Evolent Health (NYSE:EVH) Trading Down 5.8% - Should You Sell?

Key Points

• Evolent Health's stock price fell by 5.8% on Wednesday, closing at $9.41 after dipping to a low of $9.44, with trading volume significantly down by 89% from the daily average.
• Equities research analysts have largely issued a "buy" rating for Evolent Health, with price targets ranging from $13.00 to $20.00, giving the stock an average target price of $17.43.
• The company reported a loss of $0.10 EPS for the last quarter, significantly missing the consensus estimate of $0.10 and posting a 31.3% decrease in revenue year-over-year.

Shares of Evolent Health, Inc (NYSE:EVH - Get Free Report) traded down 5.8% during trading on Wednesday . The company traded as low as $9.44 and last traded at $9.41. 301,045 shares were traded during mid-day trading, a decline of 89% from the average session volume of 2,651,254 shares. The stock had previously closed at $9.99.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. BTIG Research reaffirmed a "buy" rating and issued a $20.00 price target on shares of Evolent Health in a research note on Tuesday, September 9th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Evolent Health in a research note on Tuesday, September 9th. Piper Sandler raised their price objective on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Thursday, August 28th. Truist Financial raised their price objective on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a research note on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Evolent Health currently has a consensus rating of "Buy" and an average price target of $17.43.

Evolent Health Price Performance

The company has a 50 day moving average price of $9.82 and a 200-day moving average price of $9.50. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -5.36 and a beta of 0.73.

Evolent Health (NYSE:EVH - Get Free Report) last announced its earnings results on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.20). The company had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The firm's quarterly revenue was down 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts predict that Evolent Health, Inc will post 0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Evolent Health by 18.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,498 shares of the technology company's stock worth $346,000 after buying an additional 5,712 shares during the period. Brighton Jones LLC acquired a new stake in Evolent Health during the 4th quarter worth about $3,927,000. Russell Investments Group Ltd. grew its holdings in Evolent Health by 28.6% during the 1st quarter. Russell Investments Group Ltd. now owns 98,105 shares of the technology company's stock worth $929,000 after acquiring an additional 21,826 shares during the period. Northern Trust Corp grew its holdings in Evolent Health by 0.7% during the 1st quarter. Northern Trust Corp now owns 1,203,501 shares of the technology company's stock worth $11,397,000 after acquiring an additional 8,637 shares during the period. Finally, Hussman Strategic Advisors Inc. grew its holdings in Evolent Health by 66.7% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the technology company's stock worth $994,000 after acquiring an additional 42,000 shares during the period.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.